(NASDAQ:SKYE) Skye also announces completion of enrollment of 26‑week extension study; 52‑week data planned, with post‑extension 13‑week follow‑up
Skye also announces completion of enrollment of 26‑week extension study; 52‑week data planned, with post‑extension 13‑week follow‑up
Related Questions
How will the upcoming 52‑week data and 13‑week follow‑up affect SKYE's near‑term stock price and valuation?
What does the completion of the 26‑week extension enrollment indicate about the trial’s timeline for Phase 2b or potential FDA submission?
How does Skye's CBeyond™ trial progress compare with similar programs from competitors, and what market share could be captured if the therapy succeeds?